含氟脲苷的多药联合化疗方案对妊娠滋养细胞肿瘤疗效评估研究

发布时间：2018-06-12 14:45

本文选题：妊娠滋养细胞肿瘤 + 氟脲苷　；参考：《中国实用妇科与产科杂志》2017年05期

【摘要】：目的探讨FEV(氟脲苷+依托泊苷+长春新碱)和FMEV(氟脲苷+甲氨蝶呤+依托泊苷+长春新碱)方案替代常用的FAV(氟脲苷+放线菌素D+长春新碱)及FAEV(氟脲苷+放线菌素D+依托泊苷+长春新碱)方案治疗妊娠滋养细胞肿瘤(GTN)的可行性。方法回顾性分析2015年8月至2016年3月在北京协和医院接受初次化疗方案为FEV或FAV(各12例)及FMEV或FAEV(各14例)的GTN患者的临床资料,两两比较FEV和FAV方案及FMEV和FAEV方案的疗效及副反应。结果 FEV和FAV组完全缓解(CR)率分别为91.7%和100%(P=0.86),耐药率8.3%和0(P=0.15),严重副反应2例和0例。FMEV和FAEV组CR率分别为78.6%和92.9%(P=0.48),耐药率21.4%和7.1%(P=0.28)。严重副反应8例和3例。结论 FEV和FMEV方案作为FAV和FAEV方案的替代方案在临床具一定的可行性。
[Abstract]:Objective to study the replacement of FAV (fluorouractin D vincristine) and FAEV (fluorouractin) by FEV (Fluorouretin etoposide vincristine) and FMEV (Fluoroureoside methotrexate etoposide vincristine) The feasibility of etoposide vincristine regimen in the treatment of gestational trophoblastic tumor (GTNN). Methods the clinical data of GTN patients who received FEV or FAV (12 cases each) and FMEV or FAEV (14 cases each) in Beijing Union Hospital from August 2015 to March 2016 were retrospectively analyzed. The efficacy and side effects of FEV and FAV regimen and FMEV and FAEV regimen were compared. Results the complete remission rate was 91.7% in FEV group and 0.86% in FAV group, and the drug resistance rate was 8.3% and 0.15%, respectively. The CR rates of 2 cases of severe side effects and 0 cases of FMEV and FAEV groups were 78.6% and 92.9%, respectively. The drug resistance rate was 21.4% and 7.1%, respectively. Severe side effects were found in 8 cases and 3 cases. Conclusion FEV and FMEV regimen is feasible in clinical practice as an alternative to FAV and FAEV regimen.
【作者单位】：中国医学科学院北京协和医学院北京协和医院妇产科;
【基金】：国家自然科学基金(81300488)
【分类号】：R737.33

【相似文献】